Tonix Pharmaceuticals Hol...
0.23
-0.03 (-10.30%)
At close: Jan 14, 2025, 3:59 PM
0.23
1.98%
Pre-market Jan 15, 2025, 06:30 AM EST
undefined%
Bid 0.23
Market Cap 42.44M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -80.39
PE Ratio (ttm) 0
Forward PE n/a
Analyst Strong Buy
Ask 0.23
Volume 45,654,981
Avg. Volume (20D) 106,750,662
Open 0.26
Previous Close 0.26
Day's Range 0.23 - 0.26
52-Week Range 0.12 - 12.48
Beta undefined

About TNXP

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, auto...

Industry Biotechnology
Sector Healthcare
IPO Date May 10, 2012
Employees 103
Stock Exchange NASDAQ
Ticker Symbol TNXP

Analyst Forecast

According to 2 analyst ratings, the average rating for TNXP stock is "Strong Buy." The 12-month stock price forecast is $53.5, which is an increase of 23457.90% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on Mar 31, 2025, during market hours.
Analysts project revenue of $3.40M, reflecting a -10.03% YoY shrinking and earnings per share of -2.97, making a -89.21% decrease YoY.
3 months ago · Source
+12.83%
Tonix Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
3 months ago · Source
+12.77%
Tonix Pharmaceuticals shares are trading higher after the company announced it submitted an NDA for TNX-102 SL to the FDA for fibromyalgia treatment. The non-opioid analgesic showed significant pain reduction in Phase 3 studies and received fast-track designation.